Health Care · Biological Products, (No Diagnostic Substances)

ALEC Alector, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 165308789 filings
Russell 2000

ALEC at a glance

Alector, Inc. (ALEC, SEC CIK 1653087) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as October 15, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Alector, Inc. (ALEC) reported revenue of $21.0 million (down 79.1% from FY2024) and a net loss of $142.9 million. Diluted EPS was -$1.39.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Alector, Inc. (ALEC) shares worth $57.9 million in 13F-HR filings.
  • In the last 90 days, ALEC insiders reported 0 open-market purchases ($0) and 5 open-market sales ($296K) on Form 4, a net sale of $296K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$21.0M
−79.1% vs prior year
Insiders · 90 days
0 buys · 5 sells
Net −$296K
13F holders
26 funds
$57.9M · −1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Collaboration revenue $162.9M, up $159.6M YoY from $3.3M, driven by GSK deferred-revenue recognition
  • Net income $124.6M vs net loss $34.7M YoY, operating margin 76.0% vs negative 1,153.4%
  • AL137/AL037 R&D $3.5M, other programs $18.5M, strongest disclosed development spending
  • Cash, equivalents and marketable securities $138.7M; operating cash outflow $108.2M for nine months
  • Genentech $100.0M upfront and October offering $75.0M gross; funding expected into second half of 2029

Risk Factors

  • Newly added financing risk: October 2026 underwritten offering and Genentech upfront payment expected to extend cash runway into the second half of 2029
  • Most material update, regulatory operations: FDA staffing reductions and policy changes may delay submissions, inspections, and clinical development timelines
  • Clinical risk: GSK discontinued PROGRESS-AD in April 2026 after interim futility analysis found nivisnebart unlikely to meet its primary endpoint
  • Competitive risk: Approved Alzheimer’s therapies lecanemab and donanemab may hinder enrollment and intensify market competition
  • Financial concentration risk: Future Genentech revenue depends on AL050 milestones, royalties, and product sales that may never occur

AI summary of the ALEC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Alector announced financial results for the quarter ended September 30, 2026
  • Exhibit 99.1 contains the detailed earnings release and financial performance data

Item EX-99.1: Item EX-99.1

  • Q3 collaboration revenue $162.9M versus $3.3M, largely one-time recognition of deferred GSK revenue after termination
  • Net income $124.6M, or $1.11 per share, versus $34.7M loss, masking underlying biotech operating performance
Filed Oct 16, 2026Full analysis →

Item 8.01: Other Events

  • Pricing press release for Alector’s public offering attached as Exhibit 99.1
  • Offering completion remains subject to customary closing conditions and market conditions

Item 1.01: Entry into a Material Definitive Agreement

  • $75.03M gross equity financing from 36.6M newly issued shares at $2.05 each
  • Significant shareholder dilution, with all shares sold by Alector rather than existing holders

Item EX-99.1: Item EX-99.1

  • Alector priced an underwritten equity offering of 36.6M shares at $2.05, creating substantial potential dilution
  • Gross proceeds expected at $75.03M before underwriting discounts and offering expenses
Filed Oct 14, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Option repricing covers approximately 4.05 million shares, reducing exercise prices to $1.87 from prior prices of $6.48 to $33.11
  • CEO Arnon Rosenthal affected on 2,421,197 options, with original exercise prices of $6.48 to $23.70

AI summaries of ALEC 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ALEC

Don't miss the next ALEC filing

  • Alerts as it files. A push when ALEC files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ALEC, by share count.
  • Ask anything. An AI agent that reads every ALEC filing and answers with sources.

ALEC alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Berkley Neil LindsayAOct 14, 2026-
Wong-Sarad GraceAOct 14, 2026-
Rosenthal ArnonAOct 14, 2026-
Berkley Neil LindsayAOct 14, 2026-
Rosenthal ArnonAOct 14, 2026-
Wong-Sarad GraceAOct 14, 2026-
Wong-Sarad GraceDOct 13, 2026-
Wong-Sarad GraceAOct 13, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$100.6M$21.0M
Operating Income-$151.7M-$145.0M-$156.0M
Net Income-$130.4M-$119.0M-$142.9M
Op. Margin--144.2%-741.3%
Net Margin--118.4%-679.2%
Balance Sheet
Total Assets-$468.3M$293.2M
Equity-$126.8M$30.6M
ROE--93.9%-466.3%
Per Share
EPS$-1.56$-1.23$-1.39
Cash Flow
Operating CF--$229.9M-$184.0M
CapEx$2.4M$1.3M$41K

Source: XBRL data in Alector, Inc. (ALEC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ALEC share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ALEC shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$57.9M
Q2 202627$65.8M
Q1 202627$71.4M
Q4 202525$49.2M
Q3 202527$129.6M
Q2 202529$64.0M
Q1 202526$41.1M
Q4 202422$59.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 209 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ALEC filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
8-KOct 16, 2026Analysis-
4Oct 15, 2026--
4Oct 15, 2026--
4Oct 15, 2026--
8-KOct 14, 2026Analysis-
8-KOct 5, 2026Analysis-
SC 13GSep 18, 2026-
4Sep 4, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
4Aug 21, 2026--
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
4Jul 9, 2026--
8-KJul 8, 2026Analysis-
8-KJun 17, 2026Analysis-
4Jun 17, 2026--
4Jun 17, 2026--
4Jun 17, 2026--
4Jun 17, 2026--
4Jun 17, 2026--
4Jun 17, 2026--
4Jun 17, 2026--

Related Health Care companies

All Health Care →

ALEC SEC filings: frequently asked questions

Are ALEC insiders buying or selling?

In the last 90 days, Alector, Inc. (ALEC) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $296,087 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ALEC stock?

As of September 30, 2026, the largest Alector, Inc. (ALEC) holders among the 13F filers tracked by SignalX were BlackRock ($14.2 million), Vanguard Capital Management LLC ($7.4 million), Merck & Co. ($6.6 million), Millennium Management ($5.6 million), Vanguard Portfolio Management LLC ($5.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ALEC's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Alector, Inc. (ALEC) reported revenue of $21.0 million (down 79.1% from FY2024) and a net loss of $142.9 million. Diluted EPS was -$1.39. The figures come from the XBRL data in the 10-K.

What did ALEC report in its latest 8-K?

Alector, Inc. (ALEC) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Alector announced financial results for the quarter ended September 30, 2026.

What are the latest ALEC SEC filings?

Alector, Inc. (ALEC) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on October 15, 2026.

What is ALEC's SEC CIK number?

Alector, Inc. (ALEC)'s SEC Central Index Key (CIK) is 1653087. EDGAR lists every ALEC filing under that number.

Ask anything about ALEC

The research agent reads ALEC's filings, financials, insider trades and 13F holders, then answers with sources.